Clinical Study Results
Research Sponsor: AstraZeneca
Drugs Studied: Durvalumab (MEDI4736) and tremelimumab (MEDI1123)
Study Title: A study to compare how treatment with durvalumab alone or treatment
with durvalumab combined with tremelimumab affect patients with cancer
of the head and neck compared to chemotherapy treatment
Thank you
Thank you to the participants who took part in the clinical study for the study drugs durvalumab
and tremelimumab. All of the participants and their family members helped researchers learn
whether these study drugs could help people who have cancer of the head and neck.
AstraZeneca sponsored this study and is now sharing the results of the study with the
participants and the public. An independent non-profit organization called CISCRP helped
prepare this summary of the study results. AstraZeneca and CISCRP hope this report helps the
participants and their families to understand and to feel proud of their important role in medical
research.
If you or your family member participated in the study and have questions about the results,
please speak with the doctor or staff at your study site.
What is happening with the study now?
The study started in September 2015. At the time this summary was written, the study was still
ongoing. As of September 2018, the participants who were in the study participated in the study
for an average of about 2 years.
The study included 736 participants. The study was completed in the following countries:
Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, Croatia, the Czech Republic, France,
Germany, Hungary, Israel, Italy, Japan, Poland, Romania, Russia, Serbia, South Korea, Spain,
Taiwan, Ukraine, and the United States.
The sponsor reviewed the data collected throughout the study and created a report of the results.
This is a summary of that report.
1